pathway
abbott deliv solid finish
guidanc set bullish tone year remain
midpoint highlight potenti pathways- libr
alin structur heart ngo contracts- abbott
reach high end remain overweight
solid finish abbott deliv organ growth bp ahead mse
one balanc print year abbott organ
growth reflect momentum believ continu discuss
nutrit rel stabl quarter improv pt
deceler china weak diagnost deceler bp delay
ngo contract headwind bp corpor
growth epd stabl sharp pt deceler cardio
neuromod acceler bp structur heart acceler bp
neuromod acceler pt return posit lsd growth diabet
deceler pt follow pt acceler libr grew
y/i declin line recent histori ep vs
mse driven top-line beat lower tax
off-set slightli higher opex exhibit summari
guidanc stronger look achiev preview guidanc
expect abbott could reach high-end receiv
stronger guid view guidanc consist expect
abbott deliv comfort guid higher outset set
bullish tone year updat model reflect organ
growth vs previous driven slightli higher expect diagnost
medic devic see alin libr mitraclip commentari
net higher top-line revenu drive ep margin guidanc
impli flat bp om expans gener in-lin
model consensu ep guidanc bracket street
adjust om bp drive ep
reflect underli gm improv off-set fx alin roll-out
invest libr mitraclip manufactur capac impact larg
off-set lower tax rate move ep
aforement higher sale ep estim essenti
unchang
driver catalyst libr mitraclip alin drove bp
growth expect similar contribut libr
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
mitraclip ncd us alin roll-out remain key catalyst along
triclip tendyn european launch portico tavr launch
libr global sale drove pt corpor growth
model libr growth contribut pt corpor
off-set extent mid-teen bgm declin drive total growth
diabet libr approv catalyst share
import step support long-term expans expect
approv drive distinct inflect rather see rel steadi
growth throughout year abbott continu focu access
us pharmaci ex-u expans
patient today see signific risk
mitraclip mitraclip sale drove bp corpor
growth expect ww growth contribut bp
corpor model us growth expect abbott receiv
ncd april may ex-u growth note increment
improv us mitraclip sale increment bp
abbott growth edward launch pascal europ see
expect launch us
alin lab drove bp corpor growth
model lab growth drive bp corpor
alin launch us though current model materi
us contribut continu roll europ learn
abbott us approv critic mass alin assay
increment bp growth year
card confid reach middl upper
portion guidanc rang potenti sourc upsid could includ
libr mitraclip alin discuss structur heart triclip
tendyn portico could collect contribut increment
drive bp growth ngo contract recoveri perhap least-
appreci upsid opportun abbott saw ngo headwind
delay contract rapid mdx although
msd-hsd diagnost guidanc assum anniversari
headwind ngo busi flow abbott would realiz
increment bp corpor growth net see path
manag transit bring robert ford take helm
march question around transit mean
strategi growth discuss see expect
broad chang abbott commit durabl growth evidenc
guidanc today chang focu intern innov extern
abbott focus organ growth gener
expect transform strateg action intermedi term
mr white stay execut chairman compani held broad
commit stay cours see manag transit
unlik major stock dynam note competitor
focus ep neuromodul see would
welcom activ abbott
abbott remain premium top bottom-lin grower remain overweight
driver abbott thesi remain strong includ peer lead organ
growth continu margin expans peer net leverag abbott
deliv prior quarter confid
outlook sustain intermedi term bp
margin expans low-dd low-teen ep growth look sustain
least next year metric top quartil among tradit larg
cap peer dont expect activ repurchas larg could see
growth-ori tuck-in exampl cardio/ neuromod pt
base ep premium large-cap peer group in-
line high-growth large-cap devic peer
price target base multipl
base case ep in-lin high growth larg cap peer
newer product launch libr mitraclip drive expans inflect
quicker expect upsid synergi robust em end market provid
tailwind nutrit stage strong recoveri larg share gain china
new product launch mitraclip inflect sustain organ growth
profil medium term margin grow per year support
libr fail gain traction us confirm mitraclip adopt slower
expect neuromodul growth slow nutrit end market take
longer recov abbott invest grow revenu offset margin
improv em slowdown persist
abbott organ growth sustain
driven broad busi momentum
key product growth libr mitraclip
abbott high exposur emerg
market consumer-direct busi
drive potenti sustain double-
digit earn growth also subject
compani em currenc exposur
highest among devic coverag
leverag opportun visibl across
nutrit diagnost epd peer
margin demonstr potenti
organ growth acceler driven
devic product launch diabet ep
heart failur
continu oper margin expans
core abbott combin cost synergi
execut st jude aler
risk achiev price
emerg market macro slowdown fx
headwind strengthen us dollar
failur libr mitraclip drive top-line
million except ep
million except ep
point
cardiovascular
cardiovascular neuromodul
sale
guidanc
dollar million except per share data
product sale
dollar million except per share data
point total
cardiovascular neuromodul
total cardiovascular neuromodul
dollar million except per share data
defer incom tax prepaid receiv
defer incom tax
s/t debt current portion lt debt
liabil deferr
common share net treasuri stock
accum comp incom
point total
dollar million except per share data
net chang work capit
net provid oper
proce purchas sale invest secur net
net use invest activ
chang short-term debt
chang long-term debt
chang equiti net tax benefit
issuanc purchas common share
proce stock option exercis
tax benefit option exercis
chang lt assets/borrow
effect exchang rate
net cash provid discontinu oper
net chang
equival bop
